Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vanguard Total Bond Market Index Fund ETF (BND) vs Moderna, Inc. (MRNA) Price & Performance

Vanguard Total Bond Market Index Fund ETFTrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

Vanguard Total Bond Market Index Fund ETF vs Moderna, Inc. — how do they compare? Vanguard Total Bond Market Index Fund ETF trades at $72.32, while Moderna, Inc. trades at $62.34 (market cap $24.18B). The key difference: Moderna, Inc. is trading nearer its 52-week high, Vanguard Total Bond Market Index Fund ETF nearer its low. Which is the better fit depends on your goals.

BNDMRNA
52-Week High
$75.17$81.80
52-Week Low
$72.15$22.36
Market Cap
$24.18B
Sector
Health
Enterprise Value
$20.33B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vanguard Total Bond Market Index Fund ETF

BND trades at $72.36, up 0.29% today, amid a bearish technical outlook with moving averages signaling sell pressure and oscillators neutral. The ETF shows consistent dividend distributions, with recent payouts of $0.25 and $0.24. News highlights institutional activity, including Boston Standard Wealth reducing its stake by 30.6% in Q2 2026 (SEC filing, 2026-08-05), while broader bond ETF inflows reached nearly $300 billion in H1 2026 (Zacks Investment Research, 2026-08-06).

The outlook remains cautious due to technical weakness and interest rate sensitivity, but BND offers income stability through dividends. Risks include Treasury yield volatility and inflation data impacts, yet it serves as a core fixed-income holding for diversification amid market uncertainty.

Moderna, Inc.

Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.

Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.

Returns comparison

Trailing returns across standard periods

About Vanguard Total Bond Market Index Fund ETF

This index measures the performance of a wide spectrum of public, investment-grade, taxable, fixed income securities in the US, including government, corporate, and international dollar-denominated bonds, as well as mortgage-backed and asset-backed securities-all with maturities of more than 1 year. All of the fund's investments will be selected through the sampling process, and at least 80% of its assets will be invested in bonds held in the index.

Read more on BND

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA